Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVYNJZ)

Drug Name
BUTAPROST Drug Info
Synonyms
Butaprost; (R)-Butaprost; 69648-38-0; UNII-HP16WVP23Y; TR-4979; HP16WVP23Y; NCGC00165753-01; Butaprostum; (1R,2R,3R)-3-Hydroxy-2-[(1E,4R)-4-hydroxy-4-(1-propylcyclobutyl)-1-butenyl]-5-oxo-cyclopentaneheptanoic acid methyl ester; Butaprostum [Latin]; Bay q 4218; Butaprost [USAN:INN:BAN]; Butaprost (free acid); AC1NSJVB; Butaprost (USAN/INN); DSSTox_RID_83186; DSSTox_CID_28919; SCHEMBL94764; DSSTox_GSID_48993; CHEMBL271896; GTPL3379; DTXSID8048993; BDBM85602; BAY-Q-4218; ZINC4215145; Tox21_113480; MFCD00867055; 1090AH; PDSP2_001674
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
5311035
ChEBI ID
CHEMBL271896
CAS Number
CAS 69648-38-0
TTD Drug ID
DMVYNJZ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Prostaglandin E2 receptor EP1 (PTGER1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AS-013 DMD7XWS Thrombosis DB61-GB90 Phase 3 [5]
PGF2alpha DM4XAU7 Solid tumour/cancer 2A00-2F9Z Clinical trial [6]
ZD6416 DM46JIR Pain MG30-MG3Z Discontinued in Phase 2 [7]
ONO-8130 DMBDCL4 Pollakiuria MF50.1 Terminated [8]
ONO-8711 DM2VRK7 Pain MG30-MG3Z Terminated [9]
U46619 DM13FX4 Discovery agent N.A. Investigative [6]
carbacyclin DMMBQYE Discovery agent N.A. Investigative [10]
PGD2 DMYDW6J Discovery agent N.A. Investigative [11]
M&B 28767 DMJQG82 Discovery agent N.A. Investigative [12]
cicaprost DM7ZJ4H Discovery agent N.A. Investigative [10]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Prostaglandin E2 receptor EP4 (PTGER4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
16,16-dimethyl-PGE2 DMNF38S Stem cell engraftment QB63.8 Phase 2 [12]
RQ-00000007 (oral) DMMYTRU Pain MG30-MG3Z Phase 2 [13]
ONO-AE1-437 DMCUGI8 Asthma CA23 Phase 2 [14]
BGC-20-1531 DMS2MQ5 Migraine 8A80 Phase 2 [15]
IK-007 DMBLFPN Non-small-cell lung cancer 2C25 Phase 1/2 [16]
TPST-1495 DM3GSB2 Solid tumour/cancer 2A00-2F9Z Phase 1 [17]
E7046 DMFVT43 Rectal adenocarcinoma 2B92 Phase 1 [18]
ONO-4232 DMO4SD2 Acute heart failure BD10-BD13 Phase 1 [19]
ONO-4578 DME63VK Solid tumour/cancer 2A00-2F9Z Phase 1 [18]
AN0025 DMGSYPY Aggressive cancer 2A00-2F9Z Phase 1 [20]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Prostaglandin E2 receptor EP2 (PTGER2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [2]
Mycophenolate mofetil DMPQAGE Hepatosplenic T-cell lymphoma Approved [21]
Alprostadil DMWH7NQ Aorta coarctation Approved [22]
Iloprost DMVPZBE Pulmonary arterial hypertension BB01.0 Approved [23]
Omidenepag isopropyl DMUX7Z8 Glaucoma/ocular hypertension 9C61 Approved [24]
LAROPIPRANT DM5FABJ Coronary heart disease BA80.Z Phase 4 [25]
16,16-dimethyl-PGE2 DMNF38S Stem cell engraftment QB63.8 Phase 2 [12]
CP-533536 DMZEJLB Osteoporosis FB83.0 Phase 2 [26]
Taprenepag DM1TSHL Glaucoma/ocular hypertension 9C61 Phase 2 [27]
TPST-1495 DM3GSB2 Solid tumour/cancer 2A00-2F9Z Phase 1 [17]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Prostaglandin F2-alpha receptor (PTGFR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [2]
Latanoprost DMI5OXG Ocular hypertension 9C61.01 Approved [28]
BOL-303259-X DM2EXC5 Open-angle glaucoma 9C61 Approved [29]
Tafluprost DMFC41K Glaucoma/ocular hypertension 9C61 Approved [30]
Carboprost Tromethamine DMS3508 Abortion JA00 Approved [31]
Travoprost DM20K91 Ocular hypertension 9C61.01 Approved [32]
LAROPIPRANT DM5FABJ Coronary heart disease BA80.Z Phase 4 [25]
PGF2ALPHA-IE DM5DAP3 Glaucoma/ocular hypertension 9C61 Phase 3 [33]
ONO-9054 DM5O6GC Glaucoma/ocular hypertension 9C61 Phase 2 [34]
PDC-41 DM74YO8 Dysmenorrhea GA34.3 Phase 1 [35]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Prostaglandin E2 receptor EP3 (PTGER3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
16,16-dimethyl-PGE2 DMNF38S Stem cell engraftment QB63.8 Phase 2 [12]
ONO-9054 DM5O6GC Glaucoma/ocular hypertension 9C61 Phase 2 [34]
PGF2alpha DM4XAU7 Solid tumour/cancer 2A00-2F9Z Clinical trial [12]
DG041 DMVO9WM Peripheral vascular disease BD4Z Discontinued in Phase 2 [36]
GR-63799X DM13GK8 Asthma CA23 Discontinued in Phase 1 [37]
U46619 DM13FX4 Discovery agent N.A. Investigative [10]
carbacyclin DMMBQYE Discovery agent N.A. Investigative [12]
PGD2 DMYDW6J Discovery agent N.A. Investigative [6]
butaprost (free acid form) DM5MZHP Discovery agent N.A. Investigative [10]
M&B 28767 DMJQG82 Discovery agent N.A. Investigative [12]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Beta-2 adrenergic receptor (ADRB2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Salmeterol DMIEU69 Allergic asthma CA23.0 Approved [38]
Bambuterol DMKLSHF Asthma CA23 Approved [39]
Terbutaline DMD4381 Asthma CA23 Approved [40]
Salbutamol DMN9CWF Acute asthma CA23 Approved [41]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [42]
Methotrexate DM2TEOL Anterior urethra cancer Approved [43]
Epinephrine DM3KJBC Acute asthma CA23 Approved [44]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [45]
Liothyronine DM6IR3P Congenital hypothyroidism Approved [46]
Ergotidine DM78IME Osteoarthritis FA00-FA05 Approved [47]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Interleukin-23 subunit alpha (IL23A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [48]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [49]
Methylprednisolone DM4BDON Acute adrenal insufficiency Approved [48]
Misoprostol DMHVJFK Medical abortion JA00.1Z Approved [4]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [50]
Azathioprine DMMZSXQ Lupus nephritis 4A40.0Y Approved [48]
Bortezomib DMNO38U Leukemia Approved [51]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [52]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [48]
Prednisolone DMQ8FR2 Acute adrenal insufficiency Approved [48]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostaglandin E2 receptor EP1 (PTGER1) TTG1QMU PE2R1_HUMAN Antagonist [2]
Prostaglandin E2 receptor EP2 (PTGER2) TT1ZAVI PE2R2_HUMAN Antagonist [2]
Prostaglandin E2 receptor EP3 (PTGER3) TTPNGDE PE2R3_HUMAN Antagonist [2]
Prostaglandin E2 receptor EP4 (PTGER4) TT79WV3 PE2R4_HUMAN Antagonist [2]
Prostaglandin F2-alpha receptor (PTGFR) TTT2ZAR PF2R_HUMAN Antagonist [2]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Beta-2 adrenergic receptor (ADRB2) OTSDOX4Q ADRB2_HUMAN Gene/Protein Processing [3]
Interleukin-23 subunit alpha (IL23A) OTYO99HC IL23A_HUMAN Gene/Protein Processing [4]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3379).
2 Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44.
3 Dual regulation of 2-adrenoceptor messenger RNA expression in human lung fibroblasts by 2-cAMP signaling; delayed upregulated inhibitors oppose a rapid in onset, direct stimulation of gene expression. Naunyn Schmiedebergs Arch Pharmacol. 2014 Jul;387(7):649-57. doi: 10.1007/s00210-014-0971-7. Epub 2014 Apr 8.
4 Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J Exp Med. 2009 Mar 16;206(3):535-48. doi: 10.1084/jem.20082293. Epub 2009 Mar 9.
5 Effect of lipo-pro-prostaglandin E1, AS-013 on rat inner ear microcirculatory thrombosis. Prostaglandins Leukot Essent Fatty Acids. 1998 Sep;59(3):203-7.
6 Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41.
7 The prostaglandin E2 receptor-1 (EP-1) mediates acid-induced visceral pain hypersensitivity in humans. Gastroenterology. 2003 Jan;124(1):18-25.
8 ONO-8130, a selective prostanoid EP1 receptor antagonist, relieves bladder pain in mice with cyclophosphamide-induced cystitis. Pain. 2011 Jun;152(6):1373-81.
9 Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development. Carcinogenesis. 2001 Dec;22(12):2001-4.
10 The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
11 Cloned human EP1 prostanoid receptor pharmacology characterized using radioligand binding techniques. J Pharm Pharmacol. 2002 Apr;54(4):539-47.
12 Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
13 Clinical pipeline report, company report or official report of Avarx.
14 An EP4 receptor agonist prevents indomethacin-induced closure of rat ductus arteriosus in vivo. Pediatr Res. 2004 Oct;56(4):586-90.
15 BGC20-1531, a novel, potent and selective prostanoid EP4 receptor antagonist: a putative new treatment for migraine headache. Br J Pharmacol. 2009 January; 156(2): 316-327.
16 Grapiprant: an EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation. Vet Med Sci. 2015 Dec 21;2(1):3-9.
17 Clinical pipeline report, company report or official report of Tempest Therapeutics.
18 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
19 ONO-4232, an EP4-selective Agonist, Improves Left Ventricular Diastolic Dysfunction and Ameliorates Acute and Chronic Heart Failure in Animal Models. Circulation. 2012; 126: A15345.
20 AN0025, a novel antagonist of PGE2-receptor E-type 4 (EP4), in combination with total neoadjuvant treatment of advanced rectal cancer. Radiother Oncol. 2023 Aug;185:109669.
21 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 341).
22 Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
23 Exploration of prostanoid receptor subtype regulating estradiol and prostaglandin E2 induction of spinophilin in developing preoptic area neurons. Neuroscience. 2007 May 25;146(3):1117-27.
24 Clinical pipeline report, company report or official report of Santen Pharmaceutical.
25 Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806.
26 Pfizer. Product Development Pipeline. March 31 2009.
27 A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension. Curr Eye Res. 2011 Sep;36(9):809-17.
28 PGF(2alpha) FP receptor contributes to brain damage following transient focal brain ischemia. Neurotox Res. 2009 Jan;15(1):62-70.
29 Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2alpha agonist, in preclinical models. Exp Eye Res. 2011 Sep;93(3):250-5.
30 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
31 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
32 Prostaglandin subtype-selective and non-selective IOP-lowering comparison in monkeys. J Ocul Pharmacol Ther. 2009 Feb;25(1):1-8.
33 Role of nitric oxide in PGF2 alpha-induced ocular hyperemia. Exp Eye Res. 1994 Oct;59(4):401-7.
34 IOP-Lowering Effect of ONO-9054, A Novel Dual Agonist of Prostanoid EP3 and FP Receptors, in Monkeys. Invest Ophthalmol Vis Sci. 2015 Apr;56(4):2547-52.
35 THG113: a novel selective FP antagonist that delays preterm labor. Semin Perinatol. 2002 Dec;26(6):389-97.
36 BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol. 2007 Sep;58(3):583-8.
37 Effects of the prostanoid EP3-receptor agonists M&B 28767 and GR 63799X on infarct size caused by regional myocardial ischaemia in the anaesthetized rat. Br J Pharmacol. 1999 Feb;126(4):849-58.
38 Pleiotropic beta-agonist-promoted receptor conformations and signals independent of intrinsic activity. Am J Respir Cell Mol Biol. 2007 Feb;36(2):236-43. doi: 10.1165/rcmb.2006-0257OC. Epub 2006 Sep 15.
39 Development of 3D-QSAR models for predicting the activities of chemicals to stimulate muscle growth via (2)-adrenoceptor. Toxicol In Vitro. 2021 Dec;77:105251. doi: 10.1016/j.tiv.2021.105251. Epub 2021 Sep 30.
40 Beta2-adrenergic receptor polymorphisms in African American children with status asthmaticus. Pediatr Crit Care Med. 2006 Jan;7(1):15-8. doi: 10.1097/01.pcc.0000194010.63115.a2.
41 beta2-adrenergic receptor polymorphisms and salbutamol-stimulated energy expenditure. J Clin Endocrinol Metab. 2005 Apr;90(4):2301-7. doi: 10.1210/jc.2004-1356. Epub 2005 Feb 1.
42 Neutrophil beta(2)-adrenoceptor function in major depression: G(s) coupling, effects of imipramine and relationship to treatment outcome. Eur J Pharmacol. 1999 Dec 15;386(2-3):135-44. doi: 10.1016/s0014-2999(99)00749-9.
43 Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
44 Myocardial ischaemia and ventricular arrhthymias precipitated by physiological concentrations of adrenaline in patients with coronary artery disease. Br Heart J. 1992 May;67(5):419-20. doi: 10.1136/hrt.67.5.419-b.
45 Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
46 Hormonal regulation of beta2-adrenergic receptor level in prostate cancer. Prostate. 2008 Jul 1;68(10):1133-42. doi: 10.1002/pros.20778.
47 Histamine augments beta2-adrenoceptor-induced cyclic AMP accumulation in human prostate cancer cells DU-145 independently of known histamine receptors. Biochem Pharmacol. 2007 Mar 15;73(6):814-23. doi: 10.1016/j.bcp.2006.11.022. Epub 2006 Dec 1.
48 Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
49 Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes. J Immunol. 2008 May 15;180(10):6988-96. doi: 10.4049/jimmunol.180.10.6988.
50 The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
51 Induction of heme oxygenase-1 by cobalt protoporphyrin enhances the antitumour effect of bortezomib in adult T-cell leukaemia cells. Br J Cancer. 2007 Oct 22;97(8):1099-105. doi: 10.1038/sj.bjc.6604003. Epub 2007 Sep 25.
52 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.